HIGH SPRINGS, FL--(Marketwire - May 28, 2009) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced today its first quarter results of operations.
Sales revenues increased 78% over last year’s comparable quarter with $121,000 in sales compared with $68,000. Cost of sales decreased during the same period by 12% reflecting a small change in product sales mix. Net operating losses decreased 20.1% for the quarter compared to the year ago period.
“We will continue to introduce new products that will increase sales revenue and implement a strategy of creating or acquiring operational affiliates and/or subsidiaries that will use Cyclodextrins in herbal medicines, waste-water remediation, pharmaceuticals, and foods,” stated Mr. Strattan, Chairman and CEO. “We also intend to pursue exclusive relationships with major Cyclodextrin manufacturer(s) and specialty Cyclodextrin labs to distribute their products. We continue to be the exclusive distributor in North America of the Cyclodextrin products manufactured by Cyclolab Research Laboratories in Budapest, Hungary.”
“Cyclodextrins have been rediscovered in the United States market as large pharmaceutical companies such as Johnson & Johnson and consumer products companies such as Procter & Gamble continue to expose the market to the uses and unique properties of Cyclodextrins,” Mr. Strattan stated, and went on to say, “Products such as Febreeze® and Bounce® are just a small part of the potential uses of Cyclodextrins, and we are on the edge of some significant break-throughs in the utilization of Cyclodextrins in health care and consumer consumables which we will be soon revealing to our shareholders and the investment community.”
Finally, Mr. Strattan added that, “As a result of our confidence in our current and future business model we have begun to re-purchase shares in the marketplace in accordance with our announcement back in October of last year. The purchases and prices paid will be filed with the SEC and reflected in our second quarter results.”
About CTD Holdings, Inc.
The company is the one-stop shop, business-to-business facilitator of commercial and research applications of Cyclodextrins. With its branded Trappsol® and Aquaplex® product offerings, CTDH scientists coordinate the development of commercial products for use in the pharmaceuticals, foods, hazardous waste treatment, and cosmetics industries, just to name a few of the industries which endeavor to put non water-soluble ingredients into water-based formulations. More recently CTDH has worked, in an advisory capacity, on the benefits and application of Cyclodextrins as a treatment for Neimann Picks disease, a debilitating childhood disease often associated with Alzheimer’s. CTDH was founded in 1990 as a Florida corporation and became a public company in 1994. Additional information on the Company can be found on the Company’s website: www.cyclodex.com
This news release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH complies with the regulations and time lines mandated by the SEC in the filing of its financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc accepts no specific responsibility for updating such statements.
Contact:
Rick Strattan
CEO
386-454-0887
